Does Medica Cover Forteo (Teriparatide)? A Complete Coverage Guide

What Is Forteo and Why Does Coverage Matter?

Forteo is a synthetic fragment of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than simply slowing bone loss. The FDA approved teriparatide on November 26, 2002, for postmenopausal women and men with osteoporosis at high risk for fracture, and later for glucocorticoid-induced osteoporosis 1. At a list price exceeding $3,000 per month for a single injection pen, insurance coverage is not optional for most patients, it is the deciding factor in whether they can access the drug at all.

The key registration trial enrolled 1,637 postmenopausal women and showed teriparatide 20 mcg/day reduced new vertebral fracture risk by 65% (relative risk 0.35 to 95% CI 0.22-0.55, P<0.001) compared with placebo over a median 19 months 2. Non-vertebral fragility fractures fell by 53% in the same cohort 2. Those numbers explain why physicians prescribe it despite its cost, and why insurers, including Medica, require rigorous justification before approving it.

Medica is a Minnesota-based nonprofit insurer offering commercial, Medicare Advantage, Medicaid (Minnesota Health Care Programs), and marketplace plans across the Upper Midwest. Each plan type carries a distinct formulary, so the answer to "does Medica cover Forteo" depends on which specific Medica product a patient holds.

How Medica Formularies Classify Forteo

Medica places Forteo on a specialty tier in virtually every formulary it publishes for commercial, Medicare Advantage, and marketplace products. Specialty-tier drugs carry the highest cost-sharing structure and, without prior authorization, a claim will be denied at the pharmacy.

On most Medica commercial formularies, Forteo appears on Tier 4 (preferred specialty) or Tier 5 (non-preferred specialty). The distinction matters because Tier 5 placement means a patient may pay 40-50% coinsurance rather than a flat specialty copay. Medica's Medicare Advantage plans frequently place teriparatide on Part D specialty tiers where the standard cost-sharing in 2025 reaches the catastrophic phase only after the patient crosses the $2,000 annual out-of-pocket cap introduced by the Inflation Reduction Act 3.

Medica Medicaid (Prepaid Medical Assistance Program, or PMAP) coverage follows Minnesota Department of Human Services preferred drug list rules. Teriparatide is listed on the Minnesota PDL but requires prior authorization, and step therapy through an oral bisphosphonate is typically required first unless contraindicated 4.

Patients should pull their specific Summary of Benefits and Coverage (SBC) and the current formulary PDF from Medica's member portal at medica.com, then search for "teriparatide" rather than "Forteo" because formularies index by generic name.

Prior Authorization Criteria Medica Typically Applies

Prior authorization is the main barrier to Forteo access. Medica's PA criteria are not publicly published in full, but they align closely with criteria used across major commercial payers and with AACE clinical practice guidelines.

The AACE 2020 Osteoporosis Clinical Practice Guidelines state: "Anabolic agents should be used as initial therapy in patients at very high risk of fracture" and define very high risk as a T-score at or below -3.0, a recent fracture within 12 months, or a FRAX 10-year major osteoporotic fracture probability exceeding 30% 5. Medica's PA forms generally mirror this threshold language.

Common criteria a prescriber must document include:

• A DXA scan confirming T-score <-2.5 at the spine, hip, or femoral neck
• At least one osteoporotic fracture, or a FRAX 10-year hip fracture probability above 3% or major fracture probability above 20%
• A documented trial of at least 12 months on an oral bisphosphonate (alendronate or risedronate) unless the patient has a contraindication such as esophageal disease, severe renal impairment (eGFR <35 mL/min/1.73m²), or documented intolerance
• Absence of contraindications listed on the FDA label, including hypercalcemia, Paget's disease, prior skeletal radiation, open epiphyses, or unexplained elevated alkaline phosphatase 1

The prescriber submits the PA request through Medica's pharmacy benefit manager. As of 2025, Medica uses Prime Therapeutics as its PBM for most commercial lines. Turnaround on standard PA requests is typically 3 business days; urgent requests are processed within 24 hours under Minnesota state insurance rules.

What a Denied Prior Authorization Means and How to Appeal

A denial is not the end. Medica must provide a written explanation within the timeframes set by Minnesota Statutes 62Q.73, and members have the right to an internal appeal followed by an external independent review 6.

The most effective appeal strategy involves the prescribing physician submitting a peer-to-peer review call with Medica's medical director. Supplying a complete bone-turnover marker panel (serum CTX, P1NP), the actual DXA printout with T-scores and Z-scores, and documentation of fracture history or fall risk substantially strengthens the case. A 2022 analysis published in the Journal of Managed Care and Specialty Pharmacy found that 38% of initial specialty-drug PA denials across Medicare Part D plans were overturned on first appeal when physicians submitted additional clinical documentation 7.

If the internal appeal fails, Minnesota's Department of Commerce administers an external review process under state law. Patients may also file a complaint with the Minnesota Department of Human Services if they are on a Medica Medicaid product.

Out-of-Pocket Costs Under Different Medica Plans

The cost gap between approved and unapproved coverage is enormous. Without coverage, a 28-day supply of Forteo carries a list price near $3 to 200 in 2025. With Medica approval and Tier 4 specialty placement, the member's cost-sharing depends on plan design.

Typical commercial plan cost-sharing after the deductible:

• Tier 4 preferred specialty: 25-33% coinsurance, often with a monthly maximum out-of-pocket cap of $150-$250 per specialty drug
• Tier 5 non-preferred specialty: 40-50% coinsurance, meaning $1,280-$1,600 monthly without assistance

Medicare Advantage members who hit the $2,000 annual out-of-pocket cap under the 2025 Inflation Reduction Act provisions pay $0 for any Part D drug for the remainder of the plan year 3. For a drug like Forteo, many patients will reach that cap in the first month of treatment.

Commercially insured patients can use Lilly's Forteo Savings Card, which has historically capped monthly cost-sharing at $25 for eligible patients, though this card cannot be used with any federal or state government insurance program including Medicare, Medicaid, or any Medica plan funded by government dollars 8.

Alternatives Medica May Prefer Over Forteo

Medica's step therapy requirements often position Forteo as second- or third-line therapy. Understanding which alternatives are preferred helps patients and prescribers plan the most efficient path to approval.

Oral bisphosphonates (first-line). Alendronate 70 mg weekly and risedronate 35 mg weekly are generic, inexpensive, and on every Medica formulary at Tier 1 or Tier 2. The Fracture Intervention Trial (FIT, N=2,027) showed alendronate reduced vertebral fracture risk by 47% over 3 years in postmenopausal women with low bone mass 9. These are the drugs Medica will expect to have been tried first.

Denosumab (Prolia). Prolia 60 mg subcutaneous injection every 6 months is a RANK-L inhibitor. The FREEDOM trial (N=7,868) showed a 68% reduction in new vertebral fractures over 36 months versus placebo 10. Medica covers Prolia under the medical benefit (not pharmacy benefit) through a physician office or infusion setting, which changes the cost-sharing calculus significantly.

Abaloparatide (Tymlos). Tymlos is a PTHrP analog approved in 2017 with a similar anabolic mechanism to Forteo. The ACTIVE trial (N=2,463) showed abaloparatide 80 mcg/day reduced new vertebral fractures by 86% versus placebo at 18 months (P<0.001) 11. Medica may prefer Tymlos over Forteo on some formularies depending on rebate negotiations, so confirming formulary tier for both drugs before prescribing is worth the extra minute.

Romosozumab (Evenity). Evenity is a sclerostin inhibitor given as two 105-mg subcutaneous injections monthly for 12 months. The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone and showed a 48% reduction in new vertebral fractures at 24 months 12. Medica covers it with PA criteria similar to those for Forteo. Prescribers should note the FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death 13.

The 24-Month Lifetime Limit on Teriparatide

The FDA label caps teriparatide use at 24 months cumulative across a patient's lifetime 1. Medica enforces this limit as part of its PA approval. Once 24 months of teriparatide claims appear in the member's prescription history, subsequent claims are denied automatically. The same lifetime cap applies to abaloparatide (Tymlos).

This limit has direct clinical consequences. AACE guidelines recommend transitioning patients to an antiresorptive agent immediately after completing anabolic therapy to preserve the bone density gains 5. The most studied transition sequence is teriparatide followed by denosumab or zoledronic acid. A randomized trial (DATA-Switch, N=94) demonstrated that switching from teriparatide to denosumab increased lumbar spine BMD by an additional 6.6% over 24 months, compared with a 1.9% decrease in patients who stopped teriparatide without antiresorptive follow-up 14.

Medica will cover the transition antiresorptive agent under its standard formulary rules, and prescribers should initiate that PA or prescription before the final Forteo injection to avoid a gap.

How to Maximize the Chance of Medica Approving Forteo

A well-prepared PA submission dramatically shortens approval time and reduces denial rates. Specific steps make a measurable difference.

First, the prescriber should use International Classification of Diseases codes precisely. ICD-10 M80.00 (age-related osteoporosis with current pathological fracture, unspecified site) signals higher acuity than M81.0 (age-related osteoporosis without current pathological fracture) and aligns with the "very high risk" language in AACE guidelines 5.

Second, the PA letter should quote the AACE 2020 statement directly: "In patients with very high fracture risk, anabolic therapy is preferred over antiresorptive therapy as initial treatment" 5. Citing a named guideline rather than stating clinical opinion carries more weight in peer-to-peer review calls.

Third, include bone-turnover markers. A serum P1NP below 25 mcg/L suggests suppressed bone formation, which supports the argument that antiresorptive therapy alone is insufficient and an anabolic agent is needed. The International Osteoporosis Foundation recommends P1NP as the reference bone formation marker 15.

Fourth, document fall history. Two or more falls in the past 12 months or a Timed Up and Go test result above 12 seconds are recognized fall-risk indicators that strengthen the case for aggressive pharmacologic intervention.

Monitoring Requirements During Forteo Therapy That Affect Coverage Continuity

Medica typically conditions PA renewals on documented monitoring. Missing labs or follow-up visits can interrupt coverage mid-course.

Standard monitoring during teriparatide therapy includes:

• Serum calcium at baseline and at one month (hypercalcemia occurs in roughly 3% of patients in clinical trials) 2
• Serum creatinine and eGFR at baseline because teriparatide is not recommended in patients with eGFR <30 mL/min/1.73m²
• Repeat DXA at 12-18 months to document response; Medica uses DXA results to justify continued treatment
• Urine calcium if dietary calcium intake is high, given teriparatide's effect on intestinal calcium absorption

The 2020 AACE guidelines recommend reassessing fracture risk at 1-2 years during anabolic therapy and setting a treatment milestone before initiating the drug 5. Documentation of that reassessment in the patient's chart provides the evidence Medica's utilization management team needs for a mid-course PA renewal.

Serum alkaline phosphatase elevation above the upper limit of normal without other explanation is a contraindication listed on the FDA label 1. If a lab result shows an elevated level during therapy, the prescriber should notify Medica's PA team proactively rather than waiting for the insurer to audit the record.

Patient Assistance Programs When Medica Coverage Falls Short

When Medica denies coverage or leaves a patient with unaffordable cost-sharing, several programs can bridge the gap.

Lilly Cares Foundation. Eli Lilly's patient assistance program provides Forteo at no cost to uninsured or underinsured patients who meet income thresholds (generally household income at or below 400% of the federal poverty level). Applications are submitted at lillycares.com. Processing takes 2-4 weeks 8.

Lilly Insulin Value Program (co-pay card for Forteo). Commercially insured patients who are not on any government program may use the Forteo savings card to cap monthly out-of-pocket costs. As noted above, this card is not valid for Medicare, Medicaid, or any government-subsidized plan.

NeedyMeds and RxAssist databases. Both nonprofit directories list state pharmaceutical assistance programs and disease-specific foundations that may fund osteoporosis medication costs for patients who do not qualify for manufacturer assistance.

340B covered entities. Patients receiving care at a Federally Qualified Health Center (FQHC) or other 340B-eligible provider may access Forteo at significantly reduced cost under the 340B Drug Pricing Program administered by the Health Resources and Services Administration 16.

Special Populations: Medica Coverage Rules That Differ From the Standard Pathway

Glucocorticoid-induced osteoporosis (GIOP). The FDA approved teriparatide for GIOP in 2019 1. The GIOP indication follows different step-therapy logic because oral bisphosphonates are also first-line for this indication per the American College of Rheumatology 2022 GIOP guidelines 17. Medica may accept a shorter bisphosphonate trial (6 months rather than 12) if the patient is on prednisone-equivalent doses of 7.5 mg/day or higher and has documented BMD loss.

Men with osteoporosis. Forteo carries an FDA-approved indication for men with primary or hypogonadal osteoporosis. Medica's PA criteria for men mirror those for postmenopausal women. A T-score at or below -2.5 at any skeletal site plus documented fracture history or high FRAX score typically satisfies coverage criteria.

Premenopausal women. This is an off-label use. Medica will generally deny coverage for teriparatide in premenopausal women unless the patient has documented severe glucocorticoid-induced bone loss with fracture history. Prescribers pursuing this indication should submit extensive documentation and expect a longer PA review period.

What Happens After the 24-Month Teriparatide Course Ends

Completing a full 24-month course of Forteo is not the end of osteoporosis management. Bone density gains from teriparatide dissipate rapidly without sequential antiresorptive therapy. The DATA-Switch trial (N=94) showed that patients who transitioned directly from teriparatide to denosumab continued to gain lumbar spine BMD at 24 months post-switch, while those who received no follow-on therapy lost bone at a rate of approximately 1.9% per year 14.

Medica covers post-teriparatide antiresorptive therapy under standard formulary rules. Options include:

• Zoledronic acid (Reclast) 5 mg IV annually, covered under the medical benefit with a separate PA requirement
• Denosumab (Prolia) 60 mg subcutaneous every 6 months, also under the medical benefit
• Oral alendronate or risedronate, Tier 1 or Tier 2 on most Medica pharmacy formularies with no PA required

The AACE 2020 guidelines specify that antiresorptive therapy should begin within 1 month of the final teriparatide dose 5. A 2018 study in the Journal of Bone and Mineral Research (N=1,139) found that patients who had a gap of more than 3 months between completing anabolic therapy and starting antiresorptive treatment lost an average of 4.2% of lumbar spine BMD within 12 months 18.

Practical Step-by-Step Guide for Medica Members Seeking Forteo Coverage

Getting Forteo approved through Medica involves a predictable sequence. Working through it methodically cuts the average approval timeline from weeks to days.

Step 1. Confirm your plan's formulary. Log into medica.com, manage to "Prescription Benefits," and search for "teriparatide." Note the tier and whether PA is listed.

Step 2. Schedule a bone density test if one has not been done in the past 24 months. Medica covers DXA scans for women 65 and older and for younger women with risk factors per USPSTF grade B recommendation 19. Men with risk factors are covered under most Medica commercial plans.

Step 3. Document bisphosphonate trial or contraindication. Your prescriber needs 12 months of pharmacy claims or a documented medical reason why bisphosphonates cannot be used.

Step 4. Your prescriber submits the PA to Prime Therapeutics (Medica's PBM for most commercial plans) with the DXA report, fracture history, FRAX calculation, and bisphosphonate trial documentation.

Step 5. If denied, request a peer-to-peer review within 5 business days. Your prescriber calls Prime Therapeutics' clinical pharmacist line and presents the case directly.

Step 6. If the peer-to-peer review fails, file a formal internal appeal. Medica must respond within 30 days for standard appeals or 72 hours for urgent appeals under Minnesota law.

Step 7. Simultaneously apply for the Lilly Cares Foundation program or the co-pay savings card to reduce cost-sharing during any approval gap.